Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia

Takuji Yamauchi, Yasuo Mori, Toshihiro Miyamoto, Kenjiro Kamezaki, Takatoshi Aoki, Asataro Yamamoto, Katsuto Takenaka, Hiromi Iwasaki, Naoki Harada, Koji Nagafuji, Takanori Teshima, Koichi Akashi

Research output: Contribution to journalArticle

Abstract

Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy. Recent prospective trials have revealed the safety and efficacy of GO as part of conditioning following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO. Primary neutrophil engraftment occurred in all cases, while recovery of platelet count was delayed. Only one case of reversible hepatic sinusoidal obstruction syndrome was documented. Non-relapse mortality at day 100 was not documented. Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early. These data suggest that GO may be safely combined with RIC for UCBT after previous allogeneic SCT.

Original languageEnglish
Pages (from-to)416-420
Number of pages5
JournalInternational journal of hematology
Volume90
Issue number3
DOIs
Publication statusPublished - Oct 1 2009

Fingerprint

Fetal Blood
Acute Myeloid Leukemia
Transplantation
Stem Cell Transplantation
Hepatic Veno-Occlusive Disease
Peripheral Blood Stem Cell Transplantation
Melphalan
Whole-Body Irradiation
Platelet Count
Neutrophils
Bone Marrow
gemtuzumab
Safety
Drug Therapy
Mortality
Liver

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia. / Yamauchi, Takuji; Mori, Yasuo; Miyamoto, Toshihiro; Kamezaki, Kenjiro; Aoki, Takatoshi; Yamamoto, Asataro; Takenaka, Katsuto; Iwasaki, Hiromi; Harada, Naoki; Nagafuji, Koji; Teshima, Takanori; Akashi, Koichi.

In: International journal of hematology, Vol. 90, No. 3, 01.10.2009, p. 416-420.

Research output: Contribution to journalArticle

@article{06c4393a8f11415ea143a479ed0d89e4,
title = "Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia",
abstract = "Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy. Recent prospective trials have revealed the safety and efficacy of GO as part of conditioning following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO. Primary neutrophil engraftment occurred in all cases, while recovery of platelet count was delayed. Only one case of reversible hepatic sinusoidal obstruction syndrome was documented. Non-relapse mortality at day 100 was not documented. Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early. These data suggest that GO may be safely combined with RIC for UCBT after previous allogeneic SCT.",
author = "Takuji Yamauchi and Yasuo Mori and Toshihiro Miyamoto and Kenjiro Kamezaki and Takatoshi Aoki and Asataro Yamamoto and Katsuto Takenaka and Hiromi Iwasaki and Naoki Harada and Koji Nagafuji and Takanori Teshima and Koichi Akashi",
year = "2009",
month = "10",
day = "1",
doi = "10.1007/s12185-009-0405-3",
language = "English",
volume = "90",
pages = "416--420",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia

AU - Yamauchi, Takuji

AU - Mori, Yasuo

AU - Miyamoto, Toshihiro

AU - Kamezaki, Kenjiro

AU - Aoki, Takatoshi

AU - Yamamoto, Asataro

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Harada, Naoki

AU - Nagafuji, Koji

AU - Teshima, Takanori

AU - Akashi, Koichi

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy. Recent prospective trials have revealed the safety and efficacy of GO as part of conditioning following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO. Primary neutrophil engraftment occurred in all cases, while recovery of platelet count was delayed. Only one case of reversible hepatic sinusoidal obstruction syndrome was documented. Non-relapse mortality at day 100 was not documented. Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early. These data suggest that GO may be safely combined with RIC for UCBT after previous allogeneic SCT.

AB - Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy. Recent prospective trials have revealed the safety and efficacy of GO as part of conditioning following allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO. Primary neutrophil engraftment occurred in all cases, while recovery of platelet count was delayed. Only one case of reversible hepatic sinusoidal obstruction syndrome was documented. Non-relapse mortality at day 100 was not documented. Notably, one patient who responded to GO survived for 6 months after UCBT in remission with excellent performance status, while the remaining cases relapsed early. These data suggest that GO may be safely combined with RIC for UCBT after previous allogeneic SCT.

UR - http://www.scopus.com/inward/record.url?scp=76449115182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76449115182&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0405-3

DO - 10.1007/s12185-009-0405-3

M3 - Article

C2 - 19697098

AN - SCOPUS:76449115182

VL - 90

SP - 416

EP - 420

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -